Ground Fluor Pharmaceuticals has signed an exclusive licensing agreement with Massachusetts General Hospital (MGH) for newly developed aryliodonium ylide chemistry.
The new chemistry has been shown to provide significant advantages in the synthesis of radiopharmaceutical agents, according to Ground Fluor, and will help in the preparation of imaging biomarkers for radiopharmaceutical labeling.
The agreement gives Ground Fluor an opportunity to expand its expertise in aryliodonium chemistry and radiopharmaceutical development, the company said. As part of the deal, Ground Fluor has the rights to commercialize the new chemical technology.
